SCHEMBL323970

SCHEMBL323970

Cc1cnc(COC(=O)N2C=Cc3ccccc3C2)s1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.34
RAB9A P51151 3/20 0.34
PKM P14618 1/20 0.34
GABRA1 P14867 1/20 0.34
GABRG2 P18507 1/20 0.34
GABRB3 P28472 1/20 0.34
GABRA5 P31644 1/20 0.34
GABRA3 P34903 1/20 0.34
GABRA2 P47869 1/20 0.34
SLC6A3 Q01959 1/20 0.33
HDAC3 O15379 1/20 0.33
KDM4E B2RXH2 1/20 0.32
ALDH1A1 P00352 1/20 0.32
NPC1 O15118 2/20 0.32
TP53 P04637 1/20 0.32
PTGIR P43119 1/20 0.32
MEN1 O00255 1/20 0.31
LMNA P02545 1/20 0.31
HBB P68871 1/20 0.31
KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL324344 0.83 L3MBTL1 (0.38) SLC6A3HDAC3KDM4EALDH1A1MEN1
SCHEMBL324577 0.81 RAB9A (0.35) SMN1; SMN2RAB9APKMGABRA1GABRG2
SCHEMBL324887 0.80 CYP3A4 (0.36) SMN1; SMN2HDAC3ALDH1A1TP53GRIN2B
SCHEMBL15056964 0.80 HDAC3 (0.41) SMN1; SMN2RAB9AHDAC3KDM4EALDH1A1
SCHEMBL29493251 0.80 HDAC3 (0.41) SMN1; SMN2RAB9AHDAC3KDM4EALDH1A1
SCHEMBL17061167 0.79 PTGDR2 (0.41) HDAC3
SCHEMBL324266 0.78 CYP1A2 (0.53) SMN1; SMN2RAB9AALDH1A1NPC1LMNA
SCHEMBL324346 0.78 P2RX4 (0.47) SMN1; SMN2RAB9AKDM4EALDH1A1NPC1
SCHEMBL324429 0.77 HDAC3 (0.36) SMN1; SMN2RAB9AHDAC3KDM4EALDH1A1
SCHEMBL324798 0.77 GRIN2B (0.40) RAB9AHDAC3KDM4EALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8575158-B2 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators ACTELION PHARMACEUTICALS LTD. (CH) 2013-11-05 US disclosed
EP-2590944-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS Actelion Pharmaceuticals Ltd. (CH) 2013-05-15 EP disclosed
US-20130109685-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD. (CH) 2013-05-02 US disclosed
WO-2012004722-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD (CH) 2012-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130109685-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS PTGER1, PTGDR, PTGDR2 SMN1; SMN2 4056/4885RAB9A 1846/4885PKM 810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.